HAVCR2 and liver cancer: JAK1 phosphorylates PD-L1 after IL-6 activation, which is essential for PD-L1's glycosylation by STT3A to protect PD-L1 from ubiquitination and degradation; the combination of IL-6 antibody and Tim-3 (T cell immunoglobulin mucin-3) antibody has been proved to be an effective therapy for liver cancer [15].